KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Property, Plant, and Equipment (Net)

Last Annual Value

1.48M

3-Year CAGR

%

5-Year CAGR

-31%

10-Year CAGR

-17%

KT

Kalaris Therapeutics Inc Competitors Analysis of Property, Plant, and Equipment (Net)

KLRS · NASDAQ
CompanyProperty, Plant, and Equipment (Net)
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.48M
N/A-45.7%N/A 
0.00
N/AN/AN/A
17.36M
-11.0%33.6%N/A
6.11M
-23.8%-9.3%N/A
140.07K
108.2%N/AN/A
47.38M
-10.1%16.4%N/A
45.22M
-3.2%-17.6%26.9%
1.20M
-52.0%-19.1%N/A
29.23M
-1.7%85.1%N/A
666.00K
-17.4%-14.7%N/A
1.34M
-5.2%7.5%55.7%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7